Quick Update for Allscripts Healthcare Solutions (MDRX) Investors

Shares of Small-cap technology company Allscripts Healthcare Solutions moved -0.1 this evening, and are now trading at $13.87 per share. On the other hand, the average analyst target price for the stock is $17.5.

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally.

Potential Allscripts Healthcare Solutions Investors Should Analyze the Following:

  • Allscripts Healthcare Solutions has moved 0.0% over the last year.

  • The company has a price to earnings growth (PEG) ratio of 2.12. A number between 0 and 1 could mean that the market is undervaluing Allscripts Healthcare Solutions's estimated growth potential

  • Its Price to Book (P/B) ratio is 1.29

Understanding Allscripts Healthcare Solutions's Operating Margins

Date Reported Total Revenue ($ k) Operating Expenses ($ k) Operating Margins (%) YoY Growth (%)
2022-02-25 1,503,037 -530,594 6 250.0
2021-02-26 1,502,700 -621,606 -4 0.0
2020-03-02 1,632,611 -673,439 -4 33.33
2019-02-22 1,617,841 -718,143 -6 -700.0
2018-02-26 1,497,708 -620,315 1 -80.0
2017-02-27 1,386,069 -528,939 5

Averaging out to -0.3% over the last 6 years, Allscripts Healthcare Solutions's operating margins also have a high coefficient of variability, which stands at 1525.8%. The firm's margins exhibit a relatively stable growth trend of 2.9%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

ON FOCUS